ESR1 and breast cancer: The present study evaluated whether a GIS threshold of ≥ 33 is also appropriate for two major breast cancer subtypes: estrogen receptor–positive (ER+) breast cancer (ER + BC) and triple-negative breast cancer (TNBC).